NetworkNewsBreaks

MondayJan 13, 2025 10:50 am

NetworkNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Projects Approximately 120% Growth in 2024 Bookings, Secures First Advantage™ System Customer Sale

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”) announced that fiscal 2024 bookings will exceed $23 million, an approximately 120% increase from 2023, and fiscal Q4 bookings reached at least $18 million, an approximately 500% rise from $3 million in Q4 2023 bookings. The company also secured its first customer purchase of a D-Wave Advantage annealing quantum computing system, the world’s largest quantum computer with over 5,000 qubits, marking a significant expansion in its revenue model by including on-premise system sales alongside its Leap™ quantum cloud service. D-Wave ended fiscal 2024 with a record approximately $178 million in cash. To view the…

Continue Reading

MondayJan 13, 2025 7:30 am

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with gross proceeds expected to total approximately $4.25 million before fees and expenses. The offering, exclusively placed by Ladenburg Thalmann & Co. Inc., is set to close on or around Jan. 10, 2025, subject to customary conditions. Proceeds will support working capital and general corporate purposes. The shares are offered under an effective Form S-3 registration statement, with a final prospectus available on the SEC's website or through Ladenburg Thalmann. To view…

Continue Reading

FridayJan 10, 2025 2:37 pm

NetworkNewsBreaks – Quantum Computing Inc. (NASDAQ: QUBT) Announces $100M Private Placement

Quantum Computing (NASDAQ: QUBT) ("QCi"), an innovative, integrated photonics and quantum optics technology company, recently announced its entry into securities purchase agreements with institutional investors for the purchase and sale of 8,163,266 shares of common stock in a private placement at a purchase price of $12.25 per share. The company expects gross proceeds of $100 million from the offering, of which it intends to use the net for working capital and general corporate purposes. With anticipated net proceeds, combined with existing cash reserves, Quantum Computing expects to have sufficient resources to continue advancing and expanding the development and manufacturing of…

Continue Reading

FridayJan 10, 2025 2:21 pm

NetworkNewsBreaks – Alphabet Inc.’s (NASDAQ: GOOGL) Financial Contribution and Stock Performance

Alphabet (NASDAQ: GOOGL, GOOG), through Google, has made headlines with its recent financial contribution to Donald Trump’s inauguration. The company has pledged $1 million, a substantial increase from its 2017 donation. This move places Google alongside other tech giants like Amazon and Meta in supporting the event. The increased donation from Google, more than triple its previous contribution, underscores the company’s growing financial involvement in political events. This aligns with a broader trend among major tech companies to engage more actively in political and social initiatives. Such contributions can influence public perception and potentially impact regulatory relationships. On the financial…

Continue Reading

FridayJan 10, 2025 1:45 pm

NetworkNewsBreaks – AEON Biopharma Inc. (NYSE: AEON) Secures $20M in Underwritten Public Offering

AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, has announced the closing of its firm commitment underwritten public offering. AEON secured approximately $20.0 million in gross proceeds from the offering, of which it intends to use the net, together with its existing cash, for general corporate purposes and working capital. As detailed in the announcement, the company granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or warrants to cover over-allotments, if any. On Jan. 7, Aegis exercised its over-allotment option with respect…

Continue Reading

FridayJan 10, 2025 11:06 am

NetworkNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Expands Stake in Italian Serie B Club Juve Stabia

Brera Holdings (NASDAQ: BREA) has increased its ownership in SS Juve Stabia, known as “The Second Team of Naples,” from 21.74% to 34.62% following the second closing of its acquisition agreement with XX Settembre, the holding company of Club President Andrea Langella. The Ireland-based international holding company, focused on a multi-club ownership ("MCO") strategy, aims to further solidify its presence in the Italian football landscape. Executive Chairman Daniel McClory highlighted the expanded stake as a step toward scaling Brera’s MCO platform and supporting Juve Stabia’s growth in Serie B. The transaction is pending regulatory approval. To view the full press…

Continue Reading

FridayJan 10, 2025 10:51 am

NetworkNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Launches Support Program for LA Wildfire-Affected Businesses

Thumzup (NASDAQ: TZUP) announced a $10,000 support program to help small businesses impacted by recent Los Angeles wildfires. The initiative offers up to $200 in Thumzup credits per location, enabling businesses to pay customers cash for social media posts on Instagram and X (formerly Twitter) to promote their operations. Existing customers can contact their Thumzup representative for credits, while new users can apply online. CEO Robert Steele emphasized the company's commitment to aiding recovery and empowering local businesses through its platform, which transforms customers into brand advocates during challenging times. To view the full press release, visit https://nnw.fm/jBYJ7 About Thumzup® Thumzup…

Continue Reading

FridayJan 10, 2025 9:40 am

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering of Common Stock and Warrants

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on advanced immunotherapies, announced plans to offer shares of its common stock and/or pre-funded warrants in a public offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. The offering's size and terms depend on market conditions and are yet to be finalized. Proceeds will support working capital and general corporate purposes. The securities will be offered under an effective shelf registration statement filed with the SEC, and interested parties can access the preliminary prospectus and accompanying documents via the SEC website or through Ladenburg Thalmann's Prospectus…

Continue Reading

WednesdayJan 08, 2025 3:05 pm

NetworkNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Expanding Exploration, Looks to Replicate Success of Flagship Project

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), a junior exploration company, is positioned to play a critical role amidst growth of copper and gold sectors. “The company’s flagship project, the Storm Copper Project, a joint initiative by Aston Bay and American West Metals, in Nunavut, Canada, made significant advancements in 2024 and is poised for further progress in 2025,” reads a recent article. “The Storm Copper Project has gained attention for its promising assay results and high-grade copper mineralization. Spring/summer 2024 marked another successful exploration season that identified extensive copper zones, demonstrating the project’s potential as a major contributor to global…

Continue Reading

WednesdayJan 08, 2025 2:19 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS. “We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash…

Continue Reading